KRAS and cholangiocarcinoma: Approximately 50% of CCA patients exhibit druggable mutations, amplifications or fusions, including those involving FGFR2, IDH1/2, KRAS, BRAF, HER2, PIK3CA, and MET, presenting opportunities for therapeutic interventions.30